NovaBay [NBY] vs Vertex [VRTX] Detailed Stock Comparison

NovaBay Pharmaceuticals, Inc.

NYSE
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: NovaBay Pharmaceuticals, Inc. wins in 5 metrics, Vertex Pharmaceuticals Inc. wins in 11 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric NovaBay Pharmaceuticals, Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) 0.04 28.40 NovaBay Pharmaceuticals, Inc.
Price-to-Book Ratio N/A 5.92 N/A
Debt-to-Equity Ratio -0.03 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -2.38 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -5.95 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 350.10% 39.60% NovaBay Pharmaceuticals, Inc.
EBITDA Margin (TTM) 350.10% 39.60% NovaBay Pharmaceuticals, Inc.
Return on Equity 95.53% 22.54% NovaBay Pharmaceuticals, Inc.
Return on Assets (TTM) -76.11% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-8.43M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return -53.82% 1.24% Vertex Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) N/A 9.22 N/A
Enterprise Value $45.09M $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio N/A 8.83 N/A
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-28.50 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.16 0.37 NovaBay Pharmaceuticals, Inc.
Short % of Float 9.79% 1.78% Vertex Pharmaceuticals Inc.

NovaBay Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

NBY
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NovaBay Pharmaceuticals, Inc.0.87%-17.14%-11.45%-21.62%-78.11%-96.05%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NovaBay Pharmaceuticals, Inc.-53.82%-98.79%-99.97%-99.99%-100.00%-100.00%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: NovaBay Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Inc.

MetricNBYVRTX
Market Information
Market Cap i$34.35M$109.45B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i186,8301,057,061
90 Day Avg. Volume i486,3461,272,097
Last Close$1.16$428.34
52 Week Range$1.08 - $99.75$362.50 - $507.92
% from 52W High-98.84%-15.67%
All-Time High$130,156.25 (Oct 22, 2007)$519.88 (Nov 04, 2024)
% from All-Time High-100.00%-17.61%
Growth Metrics
Quarterly Revenue Growth-2.00%0.10%
Quarterly Earnings Growth-1.23%0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i3.50%0.40%
Return on Equity (TTM) i0.96%0.23%
Debt to Equity (MRQ) i-0.0310.91
Cash & Liquidity
Book Value per Share (MRQ)$-0.92$73.49
Cash per Share (MRQ)$0.30$26.01
Operating Cash Flow (TTM) i$2.70M$3.63B
Levered Free Cash Flow (TTM) i$-4,935,750$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i$0.00N/A

Valuation & Enterprise Metrics Analysis: NovaBay Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Inc.

MetricNBY (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i0.0428.40
Forward P/E i-2.3819.95
PEG Ratio i-2.380.88
Price to Sales (TTM) iN/A9.22
Price to Book (MRQ) iN/A5.92
Market Capitalization
Market Capitalization i$34.35M$109.45B
Enterprise Value i$45.09M$105.96B
Enterprise Value Metrics
Enterprise to Revenue iN/A8.83
Enterprise to EBITDA i-5.9521.78
Risk & Other Metrics
Beta i0.160.37
Book Value per Share (MRQ) i$-0.92$73.49

Financial Statements Comparison: NovaBay Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBY (2025)VRTX (2025)
Revenue/Sales i012.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i-13.8%
Gross Profit iN/A10.35B
Gross Margin i-86.2%
Research & Development iN/A4.04B
Operating Income (EBIT) i-7.59M4.55B
Operating Margin i-37.9%
EBITDA i-7.47M5.25B
EBITDA Margin i-43.7%
Pre-Tax Income i-33.22M4.64B
Pre-Tax Income % of Revenue i-38.7%
Income Tax iN/A690.00M
Income Tax % of Revenue i-5.7%
Net Income (Profit) i-22.14M3.95B
Profit Margin i-32.9%

Balance Sheet & Liquidity Metrics

MetricNBY (2025)VRTX (2025)
Cash & Equivalents i7.96M5.08B
Total Current Assets i8.68M11.20B
Total Current Assets % of Revenue i-93.3%
Total Current Liabilities i1.14M3.86B
Total Current Liabilities % of Revenue i-32.2%
Long-Term Debt i287,0001.95B
Long-Term Debt % of Revenue i-16.3%
Total Shareholders Equity i-23.18M18.67B
Retained Earnings i-210.42M13.56B
Retained Earnings % of Revenue i-113.0%
Property, Plant & Equipment i01.56B

Cash Flow Statement Comparison

MetricNBY (2025)VRTX (2025)
Operating Cash Flow i-33.33M3.77B
Operating Cash Flow % of Revenue i-31.4%
Capital Expenditures iN/A-437.60M
Free Cash Flow i-8.43M3.19B
FCF Margin i-26.6%
Debt Repayment i-2.50M-5.40M
Common Stock Repurchase i-175,000-2.39B

Short Interest & Institutional Ownership Analysis

MetricNBYVRTX
Shares Short i333,1204.02M
Short Ratio i0.692.80
Short % of Float i9.79%1.78%
Shares Outstanding i25.22M253.99M
Float Shares i2.62M253.24M
% Held by Insiders i90.14%0.21%
% Held by Institutions i5.34%97.60%
% Held by Public i4.52%2.19%

Dividend Analysis & Yield Comparison: NovaBay Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Inc.

MetricNBYVRTX
Last 12-Month Dividend i$0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i$0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i$0.00N/A
Ex-Dividend DateN/AN/A